Cargando…
What do clinicians need to watch for with direct‐acting antiviral therapy?
INTRODUCTION: The introduction of drugs targeting the virus replication cycle has revolutionized treatment of chronic hepatitis C virus. These drugs, called direct‐acting antivirals, have brought about extremely high rates of virological cure and have increased the number of patients who can receive...
Autores principales: | Aghemo, Alessio, Piroth, Lionel, Bhagani, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978638/ https://www.ncbi.nlm.nih.gov/pubmed/29633552 http://dx.doi.org/10.1002/jia2.25076 |
Ejemplares similares
-
Managing HIV/hepatitis C co-infection in the era of direct acting antivirals
por: Rockstroh, Jürgen K, et al.
Publicado: (2013) -
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2019) -
WHAT CLINICIANS NEED TO KNOW ABOUT ANTIVIRAL DRUGS AND VIRAL RESISTANCE
por: Hodinka, Richard L.
Publicado: (1997) -
Mental Healthcare Act 2017: Need to Wait and Watch
por: Mishra, Abhisek, et al.
Publicado: (2018) -
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2020)